These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1746534)

  • 81. High doses of cytosine arabinoside (HD-Ara-C) as reinforcement during remission of acute myeloid leukemia.
    Zittoun R; Marie JP; Pommier Y; Pochat L
    Med Pediatr Oncol; 1982; 10 Suppl 1():259-61. PubMed ID: 6962322
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemia.
    Preisler HD; Raza A; Larson R; Browman G; Goldberg J; Grunwald H; Vogler R; Bennett J; Gottlieb A; D'Arrigo P
    Cancer Chemother Pharmacol; 1986; 18(3):257-60. PubMed ID: 3802381
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Cell differentiation and therapeutic effect of low doses of cytosine arabinoside in human myeloid leukemia.
    Michalewicz R; Lotem J; Sachs L
    Leuk Res; 1984; 8(5):783-90. PubMed ID: 6593509
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Low-dose cytosine arabinoside in patients with acute myeloblastic leukemia and myelodysplastic syndrome.
    Heyll A; Aul C; Heyll U; Schneider W
    Haematol Blood Transfus; 1987; 30():322-5. PubMed ID: 3476364
    [No Abstract]   [Full Text] [Related]  

  • 85. Toxicity study of cytosine arabinoside and methotrexate in the maintenance therapy of childhood leukemia. A Southwest Oncology Group study.
    Nitschke R; Komp DM; Morgan SK; Starling KA; Vietti TJ
    J Clin Pharmacol; 1978; 18(2-3):131-5. PubMed ID: 272368
    [TBL] [Abstract][Full Text] [Related]  

  • 86. High-dose cytosine arabinoside and retinol in the treatment of acute myelogenous leukemia in childhood.
    Lie SO; Slørdahl SH
    Haematol Blood Transfus; 1987; 30():399-402. PubMed ID: 3476372
    [No Abstract]   [Full Text] [Related]  

  • 87. Therapy of childhood acute nonlymphocytic leukemia: the Pediatric Oncology Group experience (1977-1988).
    Steuber CP; Culbert SJ; Ravindranath Y; Krischer J; Ragab A; Civin C; Inoue S; Ruymann F; Leventhal B; Wilkinson R
    Haematol Blood Transfus; 1990; 33():198-209. PubMed ID: 2182412
    [No Abstract]   [Full Text] [Related]  

  • 88. Treatment of acute myelocytic leukemia with low-dose cytosine arabinoside: results of a pilot study in four patients.
    Hagenbeek A; Sizoo W; Löwenberg B
    Leuk Res; 1983; 7(3):443-6. PubMed ID: 6350731
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Cerebellar dysfunction during high dose cytosine arabinoside therapy in a case of acute myelogenous leukaemia.
    Cold S
    Scand J Haematol; 1986 Feb; 36(2):165-7. PubMed ID: 3458292
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The efficiency of strict reverse isolation and antimicrobial decontamination in remission induction therapy of acute leukemia.
    Kurrle E; Bhaduri S; Heimpel H; Hoelzer D; Krieger D; Vanek E; Kubanek B
    Blut; 1980 Mar; 40(3):187-95. PubMed ID: 6928791
    [TBL] [Abstract][Full Text] [Related]  

  • 91. High-dose cytosine arabinoside: advances in clinical pharmacology and therapeutic results.
    Woodruff RK; Wiley JS
    Aust N Z J Med; 1983 Dec; 13(6):561-3. PubMed ID: 6586146
    [No Abstract]   [Full Text] [Related]  

  • 92. Cell kinetic responses in childhood acute nonlymphocytic leukemia during high-dose therapy with cytosine arabinoside.
    Smets LA; Taminiau J; Hählen K; de Waal F; Behrendt H
    Blood; 1983 Jan; 61(1):79-84. PubMed ID: 6848148
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [Treatment of patients with acute nonlymphoblastic leukemia with low doses of cytarabine].
    Shvidel' LM; Iavorkovskiĭ LI; Zile MA; Klutse GK
    Gematol Transfuziol; 1989 Jan; 34(1):3-8. PubMed ID: 2721900
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Cytosine arabinoside induced liver damage: histopathologic demonstration.
    Pizzuto J; Avilés A; Ramos E; Cervera J; Aguirre J
    Med Pediatr Oncol; 1983; 11(4):287-90. PubMed ID: 6577264
    [TBL] [Abstract][Full Text] [Related]  

  • 95. High-dose cytosine arabinoside: pharmacological and clinical aspects.
    Peters WG; Colly LP; Willemze R
    Blut; 1988 Jan; 56(1):1-11. PubMed ID: 3276364
    [No Abstract]   [Full Text] [Related]  

  • 96. Low-dose cytosine arabinoside as an alternative treatment for acute leukemia in Jehovah's Witnesses.
    Dainer PM; Knupp CL; Sartiano GP
    Am J Hematol; 1992 Jun; 40(2):156-7. PubMed ID: 1585917
    [No Abstract]   [Full Text] [Related]  

  • 97. Sweet's syndrome and Pneumocystis carinii pneumonia: two sequelae of low-dose cytosine arabinoside therapy in a patient with acute myeloid leukemia.
    Chowdhary V; Nityanand S; Prasad KN; Pandey R; Dabadghao S
    Eur J Haematol; 2000 Jul; 65(1):72-3. PubMed ID: 10914942
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Hypoplastic acute myeloid leukaemia with 7 years of complete remission by low-dose cytosine arabinoside therapy alone.
    Mori H; Fuchigami K; Nagai K; Kohno T; Maeda T; Nakamura H; Kuriyama K; Izumikawa K; Tomonaga M
    Eur J Haematol; 1995 Jul; 55(1):59-60. PubMed ID: 7615052
    [No Abstract]   [Full Text] [Related]  

  • 99. Septicemia due to Streptococcus mitis in neutropenic patients with acute leukemia.
    Arning M; Gehrt A; Aul C; Runde V; Hadding U; Schneider W
    Blut; 1990 Dec; 61(6):364-8. PubMed ID: 2291985
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Acute myelogenous leukemia of unfavourable prognosis treated with retinoic acid, vitamin D3, alpha-interferon and low doses of cytosine arabinoside.
    Robèrt KH; Hellström E; Einhorn S; Gahrton G
    Scand J Haematol Suppl; 1986; 44():61-74. PubMed ID: 3008320
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.